JP2021513965A5 - - Google Patents
Info
- Publication number
- JP2021513965A5 JP2021513965A5 JP2020543314A JP2020543314A JP2021513965A5 JP 2021513965 A5 JP2021513965 A5 JP 2021513965A5 JP 2020543314 A JP2020543314 A JP 2020543314A JP 2020543314 A JP2020543314 A JP 2020543314A JP 2021513965 A5 JP2021513965 A5 JP 2021513965A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- compound
- approximately
- disease
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023177591A JP2023171662A (ja) | 2018-02-16 | 2023-10-13 | アゾロピリミジン化合物による投薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862710394P | 2018-02-16 | 2018-02-16 | |
| US62/710,394 | 2018-02-16 | ||
| PCT/US2019/018009 WO2019161054A1 (en) | 2018-02-16 | 2019-02-14 | Dosing with an azolopyrimidine compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177591A Division JP2023171662A (ja) | 2018-02-16 | 2023-10-13 | アゾロピリミジン化合物による投薬 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021513965A JP2021513965A (ja) | 2021-06-03 |
| JP2021513965A5 true JP2021513965A5 (https=) | 2022-02-21 |
| JPWO2019161054A5 JPWO2019161054A5 (https=) | 2022-02-21 |
| JP7417527B2 JP7417527B2 (ja) | 2024-01-18 |
Family
ID=67619607
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543314A Active JP7417527B2 (ja) | 2018-02-16 | 2019-02-14 | アゾロピリミジン化合物による投薬 |
| JP2023177591A Pending JP2023171662A (ja) | 2018-02-16 | 2023-10-13 | アゾロピリミジン化合物による投薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177591A Pending JP2023171662A (ja) | 2018-02-16 | 2023-10-13 | アゾロピリミジン化合物による投薬 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11478479B2 (https=) |
| EP (1) | EP3755333A4 (https=) |
| JP (2) | JP7417527B2 (https=) |
| KR (1) | KR102823186B1 (https=) |
| CN (1) | CN111818923A (https=) |
| AU (1) | AU2019222747B2 (https=) |
| CA (1) | CA3090922A1 (https=) |
| TW (1) | TWI879727B (https=) |
| WO (1) | WO2019161054A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3090922A1 (en) | 2018-02-16 | 2019-08-22 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
| EP3823614A4 (en) | 2018-07-18 | 2022-03-30 | Arcus Biosciences, Inc. | SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND |
| WO2020185859A1 (en) | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| US12310965B2 (en) | 2019-03-29 | 2025-05-27 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| CN113121502A (zh) * | 2019-12-31 | 2021-07-16 | 山东铂源生物医药有限公司 | 一种杂芳烃类化合物、中间体、组合物及应用 |
| KR102646627B1 (ko) * | 2021-03-24 | 2024-03-13 | 주식회사 스탠다임 | 아데노신 a2a 수용체 및 아데노신 a2b 수용체의 이중 길항제, 및 이의 용도 |
| WO2024097736A1 (en) * | 2022-11-02 | 2024-05-10 | Arcus Biosciences, Inc. | Processes for preparing azolopyrimidine compounds |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI330183B (https=) | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| JP2007514003A (ja) | 2003-12-15 | 2007-05-31 | アルミラル プロデスファルマ アーゲー | アデノシン受容体アンタゴニストとしての２，６−ビスヘテロアリール−４−アミノピリミジン |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| ES2365960B1 (es) | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| DE102011008352A1 (de) | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| US9593118B2 (en) | 2015-04-08 | 2017-03-14 | Lewis And Clark Pharmaceuticals, Inc. | Xanthine-substituted alkynyl carbamates/reverse carbamates as A2B antagonists |
| SI3334431T1 (sl) | 2015-08-11 | 2020-01-31 | Novartis Ag | 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka |
| CN110214012B (zh) * | 2017-01-20 | 2023-05-09 | 艾库斯生物科学有限公司 | 用于治疗癌症相关疾病的唑嘧啶 |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| RU2019133646A (ru) | 2017-03-30 | 2021-04-30 | Ф. Хоффманн-Ля Рош Аг | Изохинолины в качестве ингибиторов hpk1 |
| AR111307A1 (es) | 2017-03-30 | 2019-06-26 | Takeda Pharmaceuticals Co | Derivados de 1,2-dihidroespiro[ciclohexan-1,3-indol] o 1,2-dihidroespiro[ciclohexan-1,3-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| WO2018237173A1 (en) * | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CA3090922A1 (en) | 2018-02-16 | 2019-08-22 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
-
2019
- 2019-02-14 CA CA3090922A patent/CA3090922A1/en active Pending
- 2019-02-14 US US16/970,054 patent/US11478479B2/en active Active
- 2019-02-14 EP EP19754719.3A patent/EP3755333A4/en active Pending
- 2019-02-14 WO PCT/US2019/018009 patent/WO2019161054A1/en not_active Ceased
- 2019-02-14 CN CN201980013867.1A patent/CN111818923A/zh active Pending
- 2019-02-14 AU AU2019222747A patent/AU2019222747B2/en active Active
- 2019-02-14 KR KR1020207026519A patent/KR102823186B1/ko active Active
- 2019-02-14 JP JP2020543314A patent/JP7417527B2/ja active Active
- 2019-02-15 TW TW108105187A patent/TWI879727B/zh active
-
2023
- 2023-03-23 US US18/188,780 patent/US20230338377A1/en not_active Abandoned
- 2023-10-13 JP JP2023177591A patent/JP2023171662A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513965A5 (https=) | ||
| JP2019516711A5 (https=) | ||
| JP2020514311A5 (https=) | ||
| KR20170084034A (ko) | 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도 | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2010523634A (ja) | Ａｚｄ２１７１およびａｚｄ６２４４またはｍｅｋ阻害剤ｉｉを含む併用療法 | |
| JP2014530181A5 (https=) | ||
| JPWO2019173188A5 (https=) | ||
| Nourbakhsh et al. | Biological and pharmacological activities of noscapine: Focusing on its receptors and mechanisms | |
| JP2017516827A5 (https=) | ||
| JP2021113228A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| JPWO2020247496A5 (https=) | ||
| TWI869511B (zh) | 治療癌症之方法 | |
| US20160067248A1 (en) | Combinations | |
| JPWO2019161054A5 (https=) | ||
| JP2021511344A5 (https=) | ||
| JP2016502540A5 (https=) | ||
| CN110522753A (zh) | 一种新型抗肿瘤药物组合物、制剂和应用 | |
| JPWO2019196764A5 (https=) | ||
| JP2020521786A5 (https=) | ||
| CA2878987C (en) | Use of vegfr-3 inhibitors for treating hepatocellular carcinoma | |
| TW202114682A (zh) | Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物 | |
| CA2569739C (en) | Antitumor effect potentiator, antitumor preparation, and method for treating cancer | |
| EP2826482A1 (en) | Novel antitumor agent comprising combination of three agents | |
| JP5409613B2 (ja) | 抗腫瘍剤、キット及び癌治療方法 |